Most Popular

Marvels

The Age of Empires: Architectural Marvels and Cultural Fusion

The Age of Empires: Architectural Marvels and Cultural Fusion
hummingbirds wing draught

Panama’s wild beauty: “I feel dozens of hummingbirds’ wing-draught

Suddenly, the road goes off the rails. Deep craters spread like a rash, then become…
UK banking system

UK banking system ‘secure’ after Credit Suisse rescue

After regulators approved a Credit Suisse rescue plan to calm bank anxiety, the UK’s central…
Grammy winning singer

Grammy-winning artist Anita Pointer passes away at age 74.

Anita Pointer, a member of the Grammy-winning Pointer Sisters, has passed away at the age…

Most Popular

- Advertisement -

categories

Lorem ipsum dolor sit amet, consectetur adipiscing elit. 

Highlights

Technology

Global Powers in 2024: Technology, Military, and Economic Influence Unpacked

As we delve into 2024, the landscape of global power is shaped by a complex interplay of technological advancements, military capabilities, and economic influence. Understanding the dynamics among leading nations requires an examination of their strategic priorities and how they leverage their strengths to assert influence on the world stage. This article unpacks the multifaceted nature of global powers, highlighting the key players in technology, military strength, and economic dominance.
Ticketing system 1

Tickets ‘broken’ after Oasis ‘chaos’, resale site chief alleges

Viagogo's business development manager, Matt Drew, stated that Saturday's ticket sale for the band's first shows in 16 years "descended into chaos." A senior official at a resale site has stated that the ticketing system for shows, including next summer's Oasis concerts, is "broken." Viagogo's business development manager, Matt Drew, said Saturday's ticket sales for the band's first shows in 16 years "descended into chaos."
- Advertisement -

Highlights

GSK shares rise as the drugmaker fights ‘meritless’ cancer accusations over its heartburn treatment.

Share It:

Table of Content

GSK has stated that it will ‘vigorously’ defend itself against any ‘baseless’ assertions that its heartburn medication Zantac raises the risk of cancer.

GSK revealed that it has been identified as a defendant in about 3,000 personal injury claims in the United States, in response to escalating fears over a potential lawsuit that brought its stock down 10% yesterday.

It faces “multiple class actions” outside the United States, including Israel, and more than 100 personal injury cases in Canada.

GSK shares rise as the drugmaker fights 'meritless' cancer accusations over its heartburn treatment.

However, the group countered that the lawsuit was “inconsistent with the scientific consensus.”

In addition, both the U.S. Food and Medicine Administration and the European Medicines Agency decided that there was “no indication of a causal link” between the drug and the development of cancer.

In 2019, GSK withdrew Zantac because it included a chemical known as a potential factor for the development of certain malignancies.

Created by GSK, the medication was made available over-the-counter in the United States by French pharmaceutical manufacturer Sanofi.

The business stated, “The overwhelming weight of scientific evidence supports the conclusion that ranitidine does not enhance the risk of cancer.

GSK will actively defend itself against all baseless assertions asserting the opposite.

GSK shares increased 2.4% in early Friday trading to 1,433.8p.

Haleon, which was spun out from GSK in July, stated that it was not a party to any Zantac claims and was “not mainly accountable” for any over-the-counter or prescription Zantac claims.

However, it cautioned that it may need to compensate both GSK and Pfizer if the two become targets of legal action.

Pfizer stated that it sold Zantac products between 1998 and 2006, therefore by the time the drug was pulled from the market in 2019 and 2020, it had already ceased sales.

Haleon shares, which were down 5% yesterday, increased 0.6% to 267.30p in Friday morning trading.

New York-traded Pfizer shares declined 3.3% to settle at $48.29 per share. The price of Sanofi shares listed in Paris rose 0.3% to €85.

Tags :

Creative Media News

Leave a Reply

Grid News

Latest Post

Creative Media News is your premier source for the latest updates in finance, technology, and world events. Our dedicated team of journalists delivers in-depth analysis, breaking news, and expert opinions to keep you informed and engaged. Whether you’re interested in stock market trends, innovative tech, or global affairs, we’ve got you covered. Stay ahead with our reliable, timely, and insightful content. Join our community of readers who trust Creative Media News for accurate, up-to-date information. Follow us for daily updates and stay connected with the world’s most important stories.

Latest News

Latest Business News

Copyright © 2024 Creative SEO Hub. All Right Reserved.